A rainy morning here in the nation’s medicine chest. Even so, there are always rays of sunshine emanating from the news. So grab a cup of coffee or tea and enjoy the warmth…

Europe Opens Its Doors To Cheaper Biogenerics (The Chicago Tribune)

ImClone Profits Fall On Charge (Yahoo/AP)

Celgene Earnings Rise On Higher Sales (Yahoo/Reuters)

And here are a couple of interesting tales you may have missed….

The indefatigable Amgen ceo, Kevin Sharer, who doesn’t know a crisis when he sees one, hopes that a new drug, denosumab, could become a “double blockbuster,” both as a twice-a-year treatment for osteoporosis and as a remedy for cancers of the bone. And so Forbes writes that for denosumab to succeed, Amgen will have to battle with Novartis and its once-a-year osteoporosis infusion, Reclast, and Merck, which is racing toward the market with its own first-of-its-kind osteoporosis pill.

The Medicines Co. is chocked full of execs from big pharma and so ceo Clive Meanwell seems to really mean it when he says the little company’s journey is like climbing the Himalayas - there are just so many ups and downs. He tells The Star-Ledger of New Jersey (which owns Pharmalot) about a bet-the-company strategy on its one product by purchasing additional marketing rights, moving into bigger headquarters and expanding the sales team.